Growth hormone treatment does not augment the anti‐diabetic effects of liraglutide in UCD‐T2DM rats

INTRODUCTION: The incretin hormone glucagon‐like peptide‐1 (GLP‐1) slows gastric emptying, increases satiety and enhances insulin secretion. GLP‐1 receptor agonists, such as liraglutide, are used therapeutically in humans to improve glycaemic control and delay the onset of type 2 diabetes mellitus (...

Descripción completa

Detalles Bibliográficos
Autores principales: Swarbrick, Michael M., Cox, Chad L., Graham, James L., Knudsen, Lotte B., Stanhope, Kimber, Raun, Kirsten, Havel, Peter J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9836246/
https://www.ncbi.nlm.nih.gov/pubmed/36480511
http://dx.doi.org/10.1002/edm2.392

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9836246/
https://www.ncbi.nlm.nih.gov/pubmed/36480511
http://dx.doi.org/10.1002/edm2.392

Ejemplares similares